StreetInsider.com News Articles

BioCryst forms seven-member scientific advisory board

Mon, 05 Oct 2026 07:00:55 -0400

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the formation of a Scientific Advisory Board (SAB) comprising seven members with backgrounds in rare disease research and drug development, according to a company statement.

The SAB will provide guidance on pipeline expansion, external innovation opportunities, translational science, clinical development, and regulatory strategy. The board will be chaired by Anthony Manning, PhD, Principal at Manning Bio Worldwide, LLC, who previously served as Chief Scientific Officer at Momenta Pharmaceuticals.

Other members include Christine Bulawa, PhD, who was involved in the preclinical development of tafamidis for transthyretin amyloidosis; Eric A. Hughes, MD, PhD, currently Executive Vice President and Chief

BioCryst forms seven-member scientific advisory board

Mon, 05 Oct 2026 07:00:55 -0400

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

Mon, 05 Oct 2026 07:00:00 -0400

—Supports BioCryst’s evolution toward a more disciplined R&D model centered on external innovation—

RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development. The SAB will provide independent scientific and strategic guidance as the Company advances its research and development strategy and builds a high value novel drug pipeline.

“The formation of BioCryst’s Scientific Advisory Board marks an important step in the evolution

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

Mon, 05 Oct 2026 07:00:00 -0400

—Supports BioCryst’s evolution toward a more disciplined R&D model centered on external innovation—

“The formation of BioCryst’s Scientific Advisory Board marks an important step in the evolution

BioCryst Pharma (BCRX) PT Raised to $13 at JPMorgan

Wed, 30 Sep 2026 09:09:13 -0400

JPMorgan analyst Jessica Fye raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $13.00 (from $12.00) while maintaining a Neutral rating.

RBC Capital Downgrades BioCryst Pharma (BCRX) to Sector Perform

Thu, 10 Sep 2026 05:11:56 -0400

RBC Capital analyst Brian Abraham downgraded BioCryst Pharma (NASDAQ: BCRX) from Outperform to Sector Perform with a price target of $11.00.

For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.

Shares of BioCryst Pharma closed at $8.81 yesterday.

TD Cowen Starts BioCryst Pharma (BCRX) at Buy

Tue, 08 Sep 2026 10:26:13 -0400

TD Cowen analyst Stacy Ku initiates coverage on BioCryst Pharma (NASDAQ: BCRX) with a Buy rating and a price target of $30.00.

The analyst comments "PHVS has reported Phase III data for oral deucritibant QD in HAE prophylaxis, with 83% attack-rate reduction in the overall population, and 87% attack-rate reduction in HAE Type 1 or 2 patients. This is competitive data, with injectable-like efficacy. Based on these results, PHVS expects to file for approval in H1:2027.

Although deucritibant is an improvement to Orladeyo's Phase III, investors still underappreciate the real-world clinical profile: the five-year retention rate for Orladeyo is impressive at ~50%,

TD Cowen Starts BioCryst Pharma (BCRX) at Buy

Tue, 08 Sep 2026 10:26:13 -0400

TD Cowen analyst Stacy Ku initiates coverage on BioCryst Pharma (NASDAQ: BCRX) with a Buy rating and a price target of $30.00.

Although deucritibant is an improvement to Orladeyo's Phase III, investors still underappreciate the real-world clinical profile: the five-year retention rate for Orladeyo is impressive at ~50%,

Japan approves BioCryst's Orladeyo for children ages 2 to 12 with HAE

Tue, 25 Aug 2026 07:02:59 -0400

BioCryst Pharmaceuticals (NASDAQ: BCRX) announced that Japan's Ministry of Health, Labor and Welfare has granted marketing approval for ORLADEYO® (berotralstat) as a once-daily prophylactic therapy for pediatric patients with hereditary angioedema (HAE) aged 2 to under 12 years.

The approval covers the granule formulation of ORLADEYO, which can be swallowed directly with water or milk, or sprinkled over soft, non-acidic food. The decision is based on interim results from the APeX-P clinical trial, which evaluated pharmacokinetics, safety, and efficacy in 29 patients aged 2 to under 12 years with HAE due to C1-inhibitor deficiency. Interim results showed the drug was generally

Japan approves BioCryst's Orladeyo for children ages 2 to 12 with HAE

Tue, 25 Aug 2026 07:02:59 -0400

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan